SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of data on iza-bren ...

-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated preclinical monotherapy efficacy profile, the ...

Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO). This is an ASCO ...

FibroGen (FGEN) announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a potential first-in-class antibody-drug ...

FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen ...

SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) ...

In this video, Joshua Brody, MD, discusses primary analysis results from LOTIS-7 and SUNMO trials, both of which are ...

Topline data were announced from a phase 3 trial evaluating Merck’s 21-valent pneumococcal conjugate vaccine, Capvaxive, in ...

On Tuesday, Enveric Biosciences’ ENVB wholly-owned subsidiary, Akos Biosciences, Inc., entered into two licensing agreements with Restoration Biologics LLC, a biotechnology company focused on treating ...

A phase 2, open-label, randomized study of livmoniplimab in combination with budigalimab versus chemotherapy in patients with metastatic urothelial carcinoma. This is an ASCO Meeting Abstract from the ...